News | November 10, 2021
Pulmatrix resolves dispute with Cipla
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
It is the world’s first DNA-based Covid vaccine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Clear aligners are a series of tight-fitting custom-made mouthpieces or orthodontic systems that are useful in correcting misaligned or crooked teeth
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
